Brand dynamics
Group Real-Time Dynamics And Cutting-Edge Information In The Field Of One Health
Time Posted：2018-12-18 20:48
The 3rd China Pharmaceutical R&D Innovation Summit and the 2018 Top 100 Chinese Pharmaceutical R&D Strength List Release, guided by China Pharmaceutical University, Chongqing Municipal Commission of Economy and Information Technology, and China Chemical Pharmaceutical Industry Association, and jointly organized by Pharma智 and China Pharmacy Magazine, was grandly held at the Chongqing Marriott Hotel from June 29th to 30th, 2018. The conference specially released the "2018 China Pharmaceutical R&D Strength Ranking" (including the general list, chemical drug list, traditional Chinese medicine list, and biological drug list), and awarded certificates to the listed companies.
Time Posted：2018-12-18 20:44
On June 23, Livzon Pharmaceutical Group Co., Ltd. announced that its wholly-owned overseas subsidiary, Livzon International Limited, and YF Pharmab Limited, a subsidiary of Yunfeng Fund, plan to jointly increase capital to Livzon Biologics Limited in the form of monetary contributions.
Time Posted：2018-12-18 20:44
LZM009 is an anti-PD-1 monoclonal antibody developed by Lizhu, and the indication for this trial is advanced solid tumors.
Time Posted：2018-12-18 20:42
Among the 44 drugs proposed for priority review by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) on June 5, 2018, two were submitted by companies affiliated with Health & Happiness Group: Levosalbutamol Hydrochloride Inhalation Solution ①, submitted by Shenzhen Tai-Tai Pharmaceutical Co., Ltd., a wholly-owned subsidiary, and Shanghai Fanyu Health Pharmaceutical Technology Co., Ltd., a holding subsidiary; and Salmeterol Xinafoate Inhalation Powder ②, submitted by Shenzhen Haibin Pharmaceutical Co., Ltd., a wholly-owned subsidiary. Both were included in the list of drug registration applications for priority review recently announced by the NMPA's Center for Drug Evaluation (CDE) (29th batch).
Zhu Baoguo: Continuous Innovation, Keeping Pace with the Great Times
Time Posted：2018-12-18 20:41
Standing at a new era and embarking on a new journey. Zhu Baoguo, chairman of HealthGen Biotech Group, stated that 2018 will be a year for HealthGen to continue increasing R&D investment and continuous innovation in the fields of biomedicine and precision medicine, giving full play to the company's scientific research and competitive advantages in monoclonal antibodies, microspheres, and respiratory drugs, and continuing to lead the upgrade of the greater health industry.
Time Posted：2018-12-18 16:51
This article is reproduced from Health World Saiberlan. The top 100 pharmaceutical companies in China have been announced! On August 4, the 2018 (35th) National Pharmaceutical Industry Information Annual Conference, hosted by the China Pharmaceutical Industry Information Center, opened in Shanghai. Coinciding with the 60th anniversary of the China Pharmaceutical Industry Information Center, the conference invited leaders from relevant departments such as the National Health Commission, the National Medical Products Administration, and the National Healthcare Security Administration.
【Flash News】| Healthy Yuan's net profit increased by 30% in the first half of the year
Time Posted：2018-12-18 16:41
Jiankangyuan released its semi-annual report. During the reporting period, the company achieved operating revenue of 5.748 billion yuan, an increase of 5.59% year-on-year; net profit attributable to shareholders of the listed company reached 426 million yuan, a year-on-year increase of approximately 30.17%. During the reporting period, Lizhu Group (excluding Lizhu monoclonal antibody) achieved operating revenue of 4.565 billion yuan, a year-on-year increase of approximately 7%; contributing approximately 303 million yuan in net profit attributable to the parent company's shareholders, a year-on-year increase of approximately 27%.
Quick Navigation
+86 755-33268688 | Service Hotline
Official WeChat Official Account
Copyright © 2025 Joincare Pharmaceutical Group Industry Co., Ltd. ALL Rights Reserve.